UK markets closed
NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.42 +0.01 (+0.01%) GOLD FUTURES
2,407.00 +24.00 (+1.01%) DOW
37,765.29 +30.18 (+0.08%) Bitcoin GBP
50,458.98 -487.74 (-0.96%)
Adaptimmune Therapeutics plc (ADAP)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:27PM EDT. Market open.
Currency in USD
Valuation measures4
| Market cap (intra-day) | 270.90M |
| Enterprise value | 149.19M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 3.54 |
| Price/book (mrq) | 6.86 |
| Enterprise value/revenue | 2.47 |
| Enterprise value/EBITDA | -1.16 |
Trading information
Stock price history
| Beta (5Y monthly) | 2.38 |
| 52-week change 3 | -22.22% |
| S&P500 52-week change 3 | 21.83% |
| 52-week high 3 | 2.0500 |
| 52-week low 3 | 0.4200 |
| 50-day moving average 3 | 1.4067 |
| 200-day moving average 3 | 0.8918 |
Share statistics
| Avg vol (3-month) 3 | 1.95M |
| Avg vol (10-day) 3 | 1.33M |
| Shares outstanding 5 | 255.56M |
| Implied shares outstanding 6 | 226.17M |
| Float 8 | 734.09M |
| % held by insiders 1 | 0.20% |
| % held by institutions 1 | 67.52% |
| Shares short (28 Mar 2024) 4 | 3.2M |
| Short ratio (28 Mar 2024) 4 | 1.64 |
| Short % of float (28 Mar 2024) 4 | 2.97% |
| Short % of shares outstanding (28 Mar 2024) 4 | 1.30% |
| Shares short (prior month 29 Feb 2024) 4 | 2.8M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 30 Mar 2018 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | -188.90% |
| Operating margin (ttm) | -21,582.68% |
Management effectiveness
| Return on assets (ttm) | -28.22% |
| Return on equity (ttm) | -187.61% |
Income statement
| Revenue (ttm) | 60.28M |
| Revenue per share (ttm) | 0.30 |
| Quarterly revenue growth (yoy) | -97.90% |
| Gross profit (ttm) | N/A |
| EBITDA | -128.2M |
| Net income avi to common (ttm) | -113.87M |
| Diluted EPS (ttm) | -0.5400 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 146.94M |
| Total cash per share (mrq) | 0.1 |
| Total debt (mrq) | 25.23M |
| Total debt/equity (mrq) | 63.87% |
| Current ratio (mrq) | 2.85 |
| Book value per share (mrq) | 0.17 |
Cash flow statement
| Operating cash flow (ttm) | -140.88M |
| Levered free cash flow (ttm) | -73.76M |
© 2024 Yahoo. All rights reserved.